TherMatrx TMx-2000 PMA Backed By Impressive Pivotal Trial Results
This article was originally published in The Gray Sheet
Executive SummaryTherMatrx' modular premarket approval application for the TMx-2000 microwave thermotherapy to treat benign prostatic hyperplasia is on track for approval by late 2000 or early 2001, following submission of the first module in April.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.